Foreword |
|
v | |
Preface |
|
vii | |
|
|
1 | (7) |
|
Effectiveness of acute pain management |
|
|
1 | (2) |
|
Adverse effects of undertreated severe acute pain |
|
|
3 | (3) |
|
Acute pain management and patient outcomes |
|
|
6 | (2) |
|
Organizational considerations |
|
|
8 | (16) |
|
|
9 | (3) |
|
|
12 | (1) |
|
|
13 | (11) |
|
Assessment of the patient with acute pain |
|
|
24 | (18) |
|
Assessment of pain and pain relief |
|
|
25 | (8) |
|
Assessment of adverse effects |
|
|
33 | (9) |
|
|
42 | (29) |
|
|
43 | (2) |
|
|
45 | (9) |
|
Predictors of opioid dose |
|
|
54 | (1) |
|
|
55 | (3) |
|
Commonly used opioid agonists |
|
|
58 | (7) |
|
Partial agonists and agonist--antagonists |
|
|
65 | (2) |
|
|
67 | (4) |
|
Pharmacology of local anesthetic drugs |
|
|
71 | (16) |
|
|
71 | (3) |
|
Efficacy of local anesthetic drugs |
|
|
74 | (1) |
|
Adverse effects of local anesthetic drugs |
|
|
75 | (5) |
|
Commonly used local anesthetic drugs |
|
|
80 | (7) |
|
Non-opioid and adjuvant analgesic agents |
|
|
87 | (28) |
|
Paracetamol (acetaminophen) |
|
|
87 | (3) |
|
Non-selective non-steroidal anti-inflammatory drugs |
|
|
90 | (5) |
|
Selective COX-2 inhibitors |
|
|
95 | (3) |
|
|
98 | (2) |
|
NMDA receptor antagonist drugs |
|
|
100 | (4) |
|
α2-Adrenergic agonist drugs |
|
|
104 | (2) |
|
|
106 | (1) |
|
|
107 | (2) |
|
|
109 | (2) |
|
Membrane-stabilizing drugs |
|
|
111 | (4) |
|
Routes of systemic opioid administration |
|
|
115 | (24) |
|
|
117 | (4) |
|
Intramuscular and subcutaneous routes |
|
|
121 | (7) |
|
|
128 | (5) |
|
|
133 | (1) |
|
|
133 | (2) |
|
|
135 | (4) |
|
Patient-controlled analgesia |
|
|
139 | (28) |
|
|
140 | (2) |
|
Analgesic and other drugs used with PCA |
|
|
142 | (1) |
|
|
143 | (5) |
|
Requirements for the safe management of PCA |
|
|
148 | (3) |
|
Management of inadequate analgesia |
|
|
151 | (2) |
|
|
153 | (2) |
|
|
155 | (5) |
|
Alternative systemic routes of PCA administration |
|
|
160 | (7) |
|
Epidurai and intrathecal analgesia |
|
|
167 | (41) |
|
|
168 | (1) |
|
|
169 | (3) |
|
Drugs used for epidurai analgesia |
|
|
172 | (11) |
|
Requirements for the safe management of epidurai analgesia |
|
|
183 | (2) |
|
Patient-controlled epidurai analgesia |
|
|
185 | (1) |
|
Management of inadequate analgesia |
|
|
186 | (2) |
|
|
188 | (1) |
|
Complications and side effects of epidurai analgesia |
|
|
188 | (9) |
|
Concurrent anticoagulant or antipiateiet medications |
|
|
197 | (4) |
|
|
201 | (7) |
|
Other regional and local analgesia |
|
|
208 | (8) |
|
Continuous peripheral nerve blockade |
|
|
208 | (4) |
|
Intra-articular analgesia |
|
|
212 | (1) |
|
|
213 | (1) |
|
|
213 | (3) |
|
Non-pharmacological therapies |
|
|
216 | (5) |
|
Psychological interventions |
|
|
216 | (2) |
|
Transcutaneous electrical nerve stimulation |
|
|
218 | (1) |
|
|
219 | (1) |
|
|
219 | (2) |
|
Acute neuropathic and persistent postacute pain |
|
|
221 | (15) |
|
Pathophysiology of neuropathic pain |
|
|
222 | (1) |
|
Clinical features of neuropathic pain |
|
|
223 | (1) |
|
Acute neuropathic pain syndromes |
|
|
224 | (3) |
|
Treatment of acute neuropathic pain |
|
|
227 | (3) |
|
Progression of acute to persistent pain |
|
|
230 | (2) |
|
|
232 | (4) |
|
|
236 | (9) |
|
|
236 | (3) |
|
|
239 | (1) |
|
Specific medical conditions |
|
|
240 | (5) |
|
|
245 | (34) |
|
|
245 | (10) |
|
|
255 | (11) |
|
Patients with a substance abuse disorder |
|
|
266 | (4) |
|
Patients with obstructive sleep apnea |
|
|
270 | (2) |
|
Pregnant or lactating patients |
|
|
272 | (2) |
|
Patients with renal or hepatic impairment |
|
|
274 | (5) |
|
Self-assessment questions |
|
|
279 | (12) |
Index |
|
291 | |